PND1 COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE IN HIGH DISEASE ACTIVITY RELAPSE REMITTING MULTIPLE SCLEROSIS IN ARGENTINA

to assess the cost-effectiveness of incorporating cladribine tablets as first line therapy compared to alternative disease-modifying drugs (DMD) in the treatment of patients with high disease activity relapsing-remitting multiple sclerosis, from the social security perspective in Argentina. A Markov model provided by Merck and developed by PAREXEL Access Consulting was adapted. It included 11 health states; 10 represented the Kurtzke’s Expanded...